Literature DB >> 17592248

Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

Nina Raben1, Shoichi Takikita, Maria G Pittis, Bruno Bembi, Suely K N Marie, Ashley Roberts, Laura Page, Priya S Kishnani, Benedikt G H Schoser, Yin-Hsiu Chien, Evelyn Ralston, Kanneboyina Nagaraju, Paul H Plotz.   

Abstract

Autophagy is a major pathway for delivery of proteins and organelles to lysosomes where they are degraded and recycled. We have previously shown excessive autophagy in a mouse model of Pompe disease (glycogen storage disease type II), a devastating myopathy caused by a deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. The autophagic buildup constituted a major pathological component in skeletal muscle and interfered with delivery of the therapeutic enzyme. To assess the role of autophagy in the pathogenesis of the human disease, we have analyzed vesicles of the lysosomal-degradative pathway in isolated single muscle fibers from Pompe patients. Human myofibers showed abundant autophagosome formation and areas of autophagic buildup of a wide range of sizes. In patients, as in the mouse model, the enormous autophagic buildup causes greater skeletal muscle damage than the enlarged, glycogenfilled lysosomes outside the autophagic regions. Clearing or preventing autophagic buildup seems, therefore, a necessary target of Pompe disease therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592248     DOI: 10.4161/auto.4591

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  56 in total

Review 1.  Newborn screening for neuropathic lysosomal storage disorders.

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 3.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

4.  The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).

Authors:  A C Nascimbeni; M Fanin; E Masiero; C Angelini; M Sandri
Journal:  Cell Death Differ       Date:  2012-05-18       Impact factor: 15.828

Review 5.  Role of autophagy in the pathogenesis of Pompe disease.

Authors:  N Raben; A Roberts; P H Plotz
Journal:  Acta Myol       Date:  2007-07

6.  Monitoring autophagy in lysosomal storage disorders.

Authors:  Nina Raben; Lauren Shea; Victoria Hill; Paul Plotz
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

7.  Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease.

Authors:  Mónica Yasmín Niño; Heidi Eliana Mateus; Dora Janeth Fonseca; Marian A Kroos; Sandra Yaneth Ospina; Juan Fernando Mejía; Jesús Alfredo Uribe; Arnold J J Reuser; Paul Laissue
Journal:  JIMD Rep       Date:  2012-04-19

8.  Autophagy in Natural History and After ERT in Glycogenosis Type II.

Authors:  Corrado Angelini; Anna C Nascimbeni; Marina Fanin
Journal:  JIMD Rep       Date:  2015-02-25

9.  Acetylated microtubules are required for fusion of autophagosomes with lysosomes.

Authors:  Rui Xie; Susan Nguyen; Wallace L McKeehan; Leyuan Liu
Journal:  BMC Cell Biol       Date:  2010-11-22       Impact factor: 4.241

10.  The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.

Authors:  Caterina Porto; Monica Cardone; Federica Fontana; Barbara Rossi; Maria Rosaria Tuzzi; Antonietta Tarallo; Maria Vittoria Barone; Generoso Andria; Giancarlo Parenti
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.